BiBBInstruments (BIBB) Q3 2025 earnings summary

Executive summary

• EndoDrill® GI officially launched in the US with TaeWoong Medical USA, marking a key milestone in commercialization efforts.

• Initial US sales began with a first commercial order of approximately $11,700, targeting select hospitals for clinical evaluation.

• Clinical data from Henry Ford Hospital and Mayo Clinic demonstrated high diagnostic accuracy and potential for superior tissue sampling compared to standard needles.

• Professor Peter Vilmann, a pioneer in endoscopic ultrasound, joined as scientific advisor, strengthening clinical development.

• Production of disposable instruments transitioned to Swedish contract manufacturer Cenova, supporting scalable and cost-effective manufacturing.

Financial highlights

• Q3 2025 net sales reached 110 KSEK, up from 0 KSEK in Q3 2024.

• Operating loss for Q3 was -2,846 KSEK, compared to -2,471 KSEK in the prior year.

• Net loss after financial items for Q3 was -2,846 KSEK, versus -2,401 KSEK year-over-year.

• For the first nine months, net sales totaled 149 KSEK, with a net loss after financial items of -9,539 KSEK.

• Cash and cash equivalents at period end were 10,731 KSEK, up from 5,755 KSEK a year earlier.

• Equity increased to 42,704 KSEK from 32,136 KSEK year-over-year.

Outlook and guidance

• Broader US launch planned for 2026, leveraging clinical experience from initial targeted rollout.

• European distribution agreement targeted for Q1 2026, with stepwise regional introduction to follow.

• Launch of EndoDrill® EBUS for lung cancer diagnostics expected by late 2026.

• Continued focus on expanding clinical evidence base through additional studies.